| 0.23 -0.013 (-5.31%) | 03-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.35 | 1-year : | 0.4 |
| Resists | First : | 0.3 | Second : | 0.34 |
| Pivot price | 0.25 |
|||
| Supports | First : | 0.22 | Second : | 0.18 |
| MAs | MA(5) : | 0.24 |
MA(20) : | 0.26 |
| MA(100) : | 0.41 |
MA(250) : | 0.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16 |
D(3) : | 18.2 |
| RSI | RSI(14): 36 |
|||
| 52-week | High : | 1.22 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PSTV ] has closed above bottom band by 21.4%. Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.24 - 0.24 | 0.24 - 0.25 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.23 - 0.23 | 0.23 - 0.23 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Fri, 27 Mar 2026
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - chartmill.com
Thu, 26 Mar 2026
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Thu, 26 Mar 2026
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - investing.com
Thu, 26 Mar 2026
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board - Stock Titan
Thu, 26 Mar 2026
Plus Therapeutics appoints Ron Andrews to board of directors - investing.com
Thu, 26 Mar 2026
Veteran tied to $15B in exits joins Plus Therapeutics board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 178 (M) |
| Shares Float | 127 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 12.9 (%) |
| Shares Short | 24,400 (K) |
| Shares Short P.Month | 11,360 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | -320.9 % |
| Return on Assets (ttm) | -65.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.1 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 5.75 |
| Price to Sales | 7.79 |
| Price to Cash Flow | -2.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|